CVN424 is a non-dopamine therapy that inhibits G protein-coupled receptor 6 (GPR6), which is an orphan receptor as it has no naturally produced agonist that activates the receptor. The GPR6 inhibition can potentially improve motor and non-motor manifestations of Parkinson’s. The drug was discovered using Cerevance’s NETSseq (Nuclear Enriched Transcript Sort sequencing) platform.
Phase III trial for Cerevance’s lead CNS ... - Cure Parkinson's
Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
At this point in time, the Phase 2 trial for CVN424 (N=62) is still in progress, and still recruiting PwPs. It is scheduled to be completed in Feb 2025.
classic.clinicaltrials.gov/...
The purpose of the press release is to report that funding has been secured for a future Phase 3 trial.
Not what you're looking for?
You may also like...
Positive results for Cerevance’s Parkinson’s drug, phase 2 of CVN424 a GPR6 inverse agonist
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s...
Photopharmics kickstarts phototherapy trial for Parkinson’s disease
The US Food and Drug Administration (FDA)-approved device targets photoreceptors in the eye...
Drug fails in Phase II trial for treating Parkinson's Disease - Exenatide (Byetta, Bydureon)
Evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, therefore the...
Fecal microbiota transplantation (FMT) therapy for Parkinson’s disease - A preliminary study in China
"The objective of this study was to assess the efficacy and safety of FMT on PD. Fifteen PD...
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...
Related Posts
- MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment
- Tavapadon Lessens Motor Symptoms in Patients with Early-stage Parkinson’s, Phase 2 Trial Finds
Electroconvulsive Therapy Intervention for Parkinson’s Disease
FYI - Phase 3 trial starting in Aug.2020 for Light Therapy (Photo Bio Modulation)
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
